Rethink mRNA-based Discovery Workflows with the Power of Automated Synthetic Biology

Rethink mRNA-based Discovery Workflows with the Power of Automated Synthetic Biology

The success of mRNA-based COVID-19 vaccines has resulted in increased opportunity for advancing mRNA as a platform for vaccine and therapeutic discovery.

This momentum brings to the forefront a need for optimizing mRNA-based discovery and development workflows. A key bottleneck in discovery workflows is acquiring synthetic mRNA for screening, validation, and optimization of candidates. Request our on-demand webinar to learn more about:

• How synthetic mRNA solutions can accelerate adoptive T-cell therapy and vaccine discovery workflows
• How to overcome traditional synthetic mRNA bottlenecks and build hundreds of candidates a week for screening and optimization
• How automating mRNA synthesis is key to advancing speed, efficiency and scope of mRNA-based discovery workflows

Presented by:

Krishna Kannan, PhD.

Senior Director, Product Development
Telesis Bio